Market Overview

UPDATE: Burrill Initiates Sangamo Biosciences at Market Outperform

Share:
Related SGMO
Sangamo Reports Presentation of New Data from Proprietary ZFP Therapeutic Programs for Lysosomal Storage Disorders at ASGCT
Sangamo BioSciences Provides Clinical Update On SB-728-T Program

Burrill initiated coverage on Sangamo Biosciences (NASDAQ: SGMO) with a Market Outperform rating and a $28.00 price target.

Burrill noted, "We believe Sangamo's innovative genome editing approach could provide novel and transformative therapeutics, which could revolutionize the treatment of genetic disorders. … We believe there is a significant upside to our valuation, given the additional opportunities embedded in the platform, not to mention ex-U.S. markets, which aren't included in our calculation."

Sangamo Biosciences closed at $8.82 on Friday.

Latest Ratings for SGMO

DateFirmActionFromTo
Apr 2015BMO CapitalInitiates Coverage onOutperform
Sep 2014JefferiesInitiates Coverage onBuy
Aug 2014JP MorganInitiates Coverage onOverweight

View More Analyst Ratings for SGMO
View the Latest Analyst Ratings

Posted-In: BurrillAnalyst Color Initiation Analyst Ratings

 

Related Articles (SGMO)

Around the Web, We're Loving...

Get Benzinga's Newsletters